AMAL vs SANGINITA: Stock Comparison
AMAL shows a higher dividend yield, faster revenue growth and a higher net margin, while SANGINITA shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AMAL leads 6; SANGINITA leads 2 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AMAL | SANGINITA |
|---|---|---|
| Sector | — | Chemicals |
| Industry | — | Specialty Chemicals |
Price
| Metric | AMAL | SANGINITA |
|---|---|---|
| Live Price | ₹722.4 | ₹15.02 |
| Day Change | -0.08% | 3.23% |
| Volume | 25,482 | 2.53 L |
| 52-Week High | ₹822 | ₹15.87 |
| 52-Week Low | ₹673.55 | ₹9.26 |
| Distance from 52W High | -12.12% | -5.36% |
Valuation
| Metric | AMAL | SANGINITA |
|---|---|---|
| Market Cap | ₹0 Cr | ₹429 Cr |
| P/E Ratio | 31.38x | 0x |
| P/B Ratio | 7.74x | 3.16x |
| EPS | ₹13.53 | ₹-1.9 |
| Book Value | ₹97.37 | ₹7.7 |
| Dividend Yield | 0.21% | 0% |
Growth
| Metric | AMAL | SANGINITA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | -40.99% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 260.84% | 0% |
| Qtr Profit Growth | 589.41% | -0.17% |
Profitability & Leverage
| Metric | AMAL | SANGINITA |
|---|---|---|
| ROE | — | -20.84% |
| ROCE | — | -13.3% |
| Net Margin | 0% | -5.49% |
| Operating Margin | — | -4.42% |
| Debt to Equity | — | 0.26x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AMAL | SANGINITA |
|---|---|---|
| Promoter Holding | 71.35% | 0%▼ 25.4 pp |
| FII Holding | 0% | 0%▼ 0.19 pp |
| DII Holding | 0.03%▲ 0.01 pp | 0% |
| Public Holding | 28.62%▼ 0.02 pp | 32%▼ 42.41 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMAL and SANGINITA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.